<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127862">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02051075</url>
  </required_header>
  <id_info>
    <org_study_id>RMB 0443-13</org_study_id>
    <secondary_id>0443-13-RMB</secondary_id>
    <nct_id>NCT02051075</nct_id>
  </id_info>
  <brief_title>Fertilizations With Immotile Sperm: Pentoxyphylline Activation Alone, or With Chemical Oocyte Activation</brief_title>
  <acronym>PXN</acronym>
  <official_title>A Randomized Controlled Trial to Compare Fertilizations With Immotile Sperm After Pentoxyphylline Activation Alone, or With Chemical Oocyte Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immotile sperm is a rather frequent problem encountered in IVF patients. Treatment is
      usually based on inducing motility with pentoxyphylline (PXN) followed by ICSI. However,
      fertilization rate with this method is still lower compared with ICSI using motile sperm.
      One of the reasons for that is the immotile sperm inability to activate the oocyte Our
      research hypothesis is that better fertilization rate can be accomplished in these cases by
      combining PXN sperm activation with Ca ionophore oocyte activation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>One month post oocyte retrieval</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstration of fetal heart activity 1 month post oocyte retrieval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>One day post oocyte retrieval</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normal, 2 pronuclei, zygote one day post ICSI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>PXN only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sperm activation with PXN before ICSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXN activation and oocyte activation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sperm activation with PXN and oocyte activation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXN sperm treatment</intervention_name>
    <description>immotile sperm activation with PXN</description>
    <arm_group_label>PXN only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sperm activation with PXN and oocyte activation</intervention_name>
    <arm_group_label>PXN activation and oocyte activation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women up to 35 years of age

          -  immotile sperm

          -  At least 6 mature eggs

        Exclusion Criteria:

          -  globozoospermia

          -  &quot;Freeze all&quot; cycles because of OHSS risk.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shahar Kol, Assistant professor</last_name>
    <phone>972-4-8543232</phone>
    <email>skol@rambam.health.gov.il</email>
  </overall_contact>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Shahar Kol MD</investigator_full_name>
    <investigator_title>Durector, IVF Unit</investigator_title>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>ICSI</keyword>
  <keyword>Asthenospermia</keyword>
  <keyword>pentoxyphylline</keyword>
  <keyword>Spermatozoa</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
